Comparison of Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand

December 11, 2020 updated by: Dr. Sunisa Sintuwong, Mettapracharak Hospital

Comparison of Exposure Rate Between Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand: A Randomized, Equivalence Controlled Trial and Multicenter Study

This study wants to compare between two types of implants in enucleation. Both of them are made from porous polyethylene but have different fabricating techniques. The investigators chose an exposure rate as a main outcome because the investigators think it is the most important outcome for the surgeons. The study hypothesis is: Is the exposure rate of a local-made polyethylene orbital implant the same as an imported one?

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Sample size assessment

  • The sample size was calculated by using an equivalence formula. From a literature and our own experiences, the success rate for Medpor and 3DP were 92% and 94% respectively, the difference (D) of the success rate between two groups was 10% and assuming a 15% of drop out rate.
  • Then allocation sequence was generated by a computerized program, using block of six with varying block size.

Data management

  • All definition of data, recruiting techniques, data collection techniques and data management flow were mentioned in the SOP.
  • After double entry technique, each case record form from each site will be sent via DataFax system to the data center at Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Thailand.
  • Then data will be validated, analyzed and reported by staff at BIOPHICS.

Plan for missing data

  • by adding a drop out rate to the sample size calculation.
  • by choosing the right patients. Actually, Thai patients have good co-operation especially in surgical research.

Statistical analysis

- Intention to treat and per protocol model would be used to see the difference between two types of implants in this project.

Study Type

Interventional

Enrollment (Actual)

105

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nakhon Pathom
      • Sam Phran, Nakhon Pathom, Thailand, 73210
        • Mettapracharak Eye Center, Mettapracharak (Wat Rai Khing) Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clinical diagnosis of phthisis bulbi, painful blindness, intraocular tumor without metastasis and severe ruptured eyeball
  • Must speak and understand Thai language well
  • Must have good consciousness

Exclusion Criteria:

  • Has a history of prior enucleation or evisceration
  • Cannot follow up for at least one year
  • Has recent eye infection within 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: local made implant (3DP)
Enucleation and local made implant (3DP) insertion
intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
EXPERIMENTAL: imported implant (Medpor)
Enucleation and imported implant (Medpor) insertion
commercial porous polyethylene

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exposure rate
Time Frame: From date of surgery until the date of first exposure, assessed up to 12 months
Exposure was defined as the separation of tissue over the anterior surface of an implant.
From date of surgery until the date of first exposure, assessed up to 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Infection rate
Time Frame: From date of surgery until the date of first infection, assessed up to 12 months
Infection was defined as the presence of pus or abscess at or around an implant. It can be diagnosed clinically or confirmed by the histopathology report after explantation.
From date of surgery until the date of first infection, assessed up to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sunisa Sintuwong, MD,MPPM,MSc, Mettapracharak (Wat Rai Khing) Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2011

Primary Completion (ACTUAL)

December 12, 2020

Study Completion (ACTUAL)

December 12, 2020

Study Registration Dates

First Submitted

March 7, 2011

First Submitted That Met QC Criteria

March 9, 2011

First Posted (ESTIMATE)

March 10, 2011

Study Record Updates

Last Update Posted (ACTUAL)

December 14, 2020

Last Update Submitted That Met QC Criteria

December 11, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • MEC1/2011

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on 3DP

3
Subscribe